var data={"title":"Epidemiology, pathophysiology, and causes of gynecomastia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology, pathophysiology, and causes of gynecomastia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/contributors\" class=\"contributor contributor_credentials\">Glenn D Braunstein, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/contributors\" class=\"contributor contributor_credentials\">Bradley D Anawalt, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/contributors\" class=\"contributor contributor_credentials\">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/contributors\" class=\"contributor contributor_credentials\">Kathryn A Martin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia, a benign proliferation of the glandular tissue of the male breast, is common in infancy, adolescence, and in middle-aged to older men. Pseudogynecomastia, which is often seen in obese men, refers to fat deposition without glandular proliferation. Gynecomastia must be differentiated from breast carcinoma, which is far less common.</p><p>The epidemiology and pathogenesis will be reviewed here. The causes, evaluation, and management are discussed separately. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-evaluation-of-gynecomastia-in-adults\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and evaluation of gynecomastia in adults&quot;</a> and <a href=\"topic.htm?path=management-of-gynecomastia\" class=\"medical medical_review\">&quot;Management of gynecomastia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DEFINITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s) (<a href=\"image.htm?imageKey=ENDO%2F72334\" class=\"graphic graphic_figure graphicRef72334 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Fat deposition without glandular proliferation is termed pseudogynecomastia and is often seen in obese men.</p><p>The most important differentiation is between gynecomastia and breast carcinoma. Carcinoma is much less common, generally unilateral, eccentric in location rather than symmetrical to the nipple, nontender, hard or firm, often fixed to the underlying tissue, and may be associated with skin dimpling, nipple retraction or discharge, and axillary lymphadenopathy [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/3\" class=\"abstract_t\">3</a>]. Less common conditions leading to breast enlargement include neurofibromas, lymphangiomas, hematomas, lipomas, and dermoid cysts. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-evaluation-of-gynecomastia-in-adults#H409071425\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and evaluation of gynecomastia in adults&quot;, section on 'Further evaluation to rule out breast cancer'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia is common in infancy, adolescence, and in middle-aged to older men. One estimate is that between 60 to 90 percent of infants have transient gynecomastia due to the high estrogenic milieu of pregnancy [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/4\" class=\"abstract_t\">4</a>]. After delivery, the gynecomastia regresses in two to three weeks.</p><p>The second peak is during puberty, with a prevalence ranging from 4 to 69 percent (<a href=\"image.htm?imageKey=ENDO%2F64368\" class=\"graphic graphic_figure graphicRef64368 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/5-12\" class=\"abstract_t\">5-12</a>]. This wide variation is probably due to differences in what is considered normal subareolar glandular tissue, observer differences, and, probably most importantly, differences in the age distribution of the adolescents examined. Pubertal gynecomastia usually has an onset between ages 10 and 12 years and peaks between ages 13 and 14 years, usually at Tanner pubertal stage 3 or above (<a href=\"image.htm?imageKey=ENDO%2F76165\" class=\"graphic graphic_table graphicRef76165 \">table 1</a>). It generally regresses within 18 months but may persist into adulthood in approximately 20 percent of affected individuals [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/6\" class=\"abstract_t\">6</a>].</p><p>The third peak of gynecomastia occurs in middle-aged and older men. The highest prevalence is at 50 to 80 years, with as many as 24 to 65 percent of men being affected (<a href=\"image.htm?imageKey=ENDO%2F64368\" class=\"graphic graphic_figure graphicRef64368 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/13-18\" class=\"abstract_t\">13-18</a>].</p><p>Although gynecomastia is usually bilateral, it is often asymmetrical and can even be unilateral [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/19,20\" class=\"abstract_t\">19,20</a>]. In a study of 36 male patients who underwent subcutaneous mastectomy for a unilateral breast mass, 30 (83 percent) had gynecomastia, four (11 percent) had lipoma, and two had breast cancer [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/20\" class=\"abstract_t\">20</a>]. The majority of patients with gynecomastia were receiving medications known to cause gynecomastia.</p><p>In<strong> </strong>adult patients with persistent gynecomastia<strong> </strong>seeking<strong> </strong>consultation for the condition, current estimates suggest the following etiologies, all of which are discussed in detail below (<a href=\"image.htm?imageKey=ENDO%2F53468\" class=\"graphic graphic_table graphicRef53468 \">table 2</a>) (see <a href=\"#H6318343\" class=\"local\">'Causes of gynecomastia'</a> below):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Persistent pubertal gynecomastia &ndash; 25 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drugs &ndash; 10 to 25 percent (<a href=\"image.htm?imageKey=ENDO%2F71421\" class=\"graphic graphic_table graphicRef71421 \">table 3</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No detectable abnormality &ndash; 25 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cirrhosis or malnutrition &ndash; 8 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypogonadism &ndash; Primary (8 percent), secondary (2 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Testicular tumors &ndash; 3 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperthyroidism &ndash; 1.5 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic kidney disease &ndash; 1 percent</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The basic mechanisms of gynecomastia include a decrease in androgen production, an increase in estrogen production, or increased availability of estrogen precursors for peripheral conversion to estrogen. Androgen receptor blockade and, in men with impaired testosterone production, decreased free testosterone due to increased binding of androgen to sex hormone-binding globulin (SHBG) are other mechanisms.</p><p>There does not appear to be any difference in the responsiveness of the male or female breast glandular tissue to hormonal stimulation. The amount of glandular proliferation and ductal differentiation depends upon an individual's breast tissue sensitivity, the hormonal milieu, and the duration and intensity of hormonal stimulation.</p><p>Estrogens induce ductal epithelial hyperplasia, ductal elongation and branching, proliferation of the periductal fibroblasts, and an increase in vascularity. The histologic picture is similar in male and female breast tissue after exposure to estrogen. In comparison, luteal phase progesterone in women leads to acinar development that is not seen in males [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/21\" class=\"abstract_t\">21</a>].</p><p>The various conditions associated with gynecomastia are usually thought to represent an imbalance between the stimulatory effect of estrogen and the inhibitory effect of androgen (<a href=\"image.htm?imageKey=ENDO%2F58706\" class=\"graphic graphic_figure graphicRef58706 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/22,23\" class=\"abstract_t\">22,23</a>]. The factors that define the net <span class=\"nowrap\">estrogen/androgen</span> balance are (<a href=\"image.htm?imageKey=ENDO%2F53166\" class=\"graphic graphic_table graphicRef53166 \">table 4</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The production of these steroids or their precursors by the three steroid-producing tissues (the adrenals, the testes, and [for the male fetus] the placenta)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The extraglandular conversion of androgens to estrogens, such as in adipose tissue</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The circulating concentration of SHBG</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The hormone target cells' ability to respond to androgens and estrogens</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">In utero</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During pregnancy, the placenta transforms dehydroepiandrosterone and dehydroepiandrosterone sulfate (derived from both the mother and fetus) to <a href=\"topic.htm?path=estrone-united-states-not-available-drug-information\" class=\"drug drug_general\">estrone</a> (E1) and estradiol (E2), which enter the fetal circulation and stimulate breast glandular proliferation, resulting in transient neonatal gynecomastia. (See <a href=\"topic.htm?path=placental-development-and-physiology#H13\" class=\"medical medical_review\">&quot;Placental development and physiology&quot;, section on 'Steroid hormones'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Estrogen in men</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In adult men, 95 percent of the circulating testosterone, 15 percent of the E2, and less than 5 percent of E1 is directly secreted by the testes (<a href=\"image.htm?imageKey=ENDO%2F58706\" class=\"graphic graphic_figure graphicRef58706 \">figure 3</a>). The major androgen secreted by the adrenal glands is androstenedione. Most of the circulating E2 and E1 are derived from the extraglandular conversion of testosterone and androstenedione to E2 and E1, respectively, by tissues including liver, skin, fat, muscle, bone, and kidney, all of which contain an aromatase enzyme. There is also a substantial amount of interconversion between testosterone and androstenedione and between E2 and E1 in extraglandular tissues via 17-hydroxysteroid dehydrogenase (17-ketosteroid reductase) enzyme [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/21,24,25\" class=\"abstract_t\">21,24,25</a>]. (See <a href=\"topic.htm?path=male-reproductive-physiology#H8\" class=\"medical medical_review\">&quot;Male reproductive physiology&quot;, section on 'Androgen synthesis'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Sex hormone-binding globulin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of androgens and estrogens that enter the circulation are relatively tightly bound to SHBG and are weakly bound to albumin. Conditions that increase SHBG concentrations will decrease free testosterone in men with impaired testosterone production. In addition, SHBG has a higher affinity for androgens than for estrogens, and therefore, any substance that displaces sex hormones from SHBG will tend to displace quantitatively more estrogens than androgens. The unbound or weakly bound androgens and estrogens enter the target cells and lead to hormone action [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/26,27\" class=\"abstract_t\">26,27</a>]. (See <a href=\"topic.htm?path=male-reproductive-physiology#H10\" class=\"medical medical_review\">&quot;Male reproductive physiology&quot;, section on 'Transport of gonadal steroids'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Imbalance between estrogen and androgen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An imbalance between estrogen and androgen action will occur if there is an absolute increase in free estrogens, a decrease in endogenous production of free androgens, an increase in the free estrogen-to-free androgen ratio, androgen insensitivity, or an estrogen-like effect of drugs (<a href=\"image.htm?imageKey=ENDO%2F58706\" class=\"graphic graphic_figure graphicRef58706 \">figure 3</a>). Some patients with gynecomastia, for example, have enhanced sensitivity of the breast tissue to normal circulating estrogen levels even in the presence of normal circulating androgen concentrations. This may reflect increased aromatization of androgens to estrogens in the breast tissue itself as increased aromatase activity has been found in pubic skin fibroblasts of patients with gynecomastia [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H612304741\"><span class=\"h2\">Obesity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some studies, body mass index (BMI) is positively correlated with both breast diameter and the presence of gynecomastia in both adolescents and adults [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/16,29\" class=\"abstract_t\">16,29</a>]. Breast adipose tissue contains the aromatase enzyme complex that converts testosterone and androstenedione to E2 and E1, respectively. Thus, it is hypothesized but not proven that an increase in breast adipose tissue due to generalized weight gain may increase local estrogen production, which in turn may stimulate breast glandular tissue proliferation in a paracrine fashion. In addition, the increase in breast fat with weight gain may lead to pseudogynecomastia, which may or may not be associated with true gynecomastia. (See <a href=\"topic.htm?path=causes-of-secondary-hypogonadism-in-males#H10238486\" class=\"medical medical_review\">&quot;Causes of secondary hypogonadism in males&quot;, section on 'Obesity'</a>.)</p><p class=\"headingAnchor\" id=\"H6318343\"><span class=\"h1\">CAUSES OF GYNECOMASTIA</span></p><p class=\"headingAnchor\" id=\"H1068114220\"><span class=\"h2\">Physiologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, physiologic gynecomastia is common and has a trimodal distribution occurring in neonatal, pubertal, and older males. The estimated prevalence of asymptomatic gynecomastia in these three age groups is 60 to 90 percent in neonates, 30 to 60 percent in adolescents, and 35 to 65 percent in men ages 50 to 69 years [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H1292581444\"><span class=\"h3\">Puberty</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most studies in pubertal boys with gynecomastia have found no differences in single-point measurements of serum concentrations of testosterone, estradiol (E2), <a href=\"topic.htm?path=estrone-united-states-not-available-drug-information\" class=\"drug drug_general\">estrone</a> (E1), or gonadotropins from those in normal boys [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/7,9,30,31\" class=\"abstract_t\">7,9,30,31</a>]. However, some reports have shown a transient increase in E2 concentration at the onset of puberty in boys who develop gynecomastia [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/7\" class=\"abstract_t\">7</a>]. These boys may also have wider fluctuations of E2 levels, with an absolute increase in 24-hour concentration of E2, which may reflect increased conversion of adrenal androgens to estrogens [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/10,32\" class=\"abstract_t\">10,32</a>]. Adrenal androgen secretion rises during adrenarche, which occurs independently of and before the maturation of the hypothalamic-pituitary-gonadal axis (gonadarche).</p><p>During puberty, the serum E2 concentrations rise to adult levels before the testosterone concentration. It is likely that this transient imbalance accounts for much of the <span class=\"nowrap\">estrogen/androgen</span> imbalance that leads to pubertal gynecomastia [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/10,14,31,33\" class=\"abstract_t\">10,14,31,33</a>].</p><p>Leptin and insulin-like growth factor-1 (IGF-1) are elevated in boys with pubertal gynecomastia compared with those without [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/34-37\" class=\"abstract_t\">34-37</a>]. The finding that pubertal gynecomastia occurs in a temporal association with peak height velocity (the time when IGF-1 levels also peak) suggests that, together with estrogens, IGF-1 <span class=\"nowrap\">and/or</span> leptin might play a role in the genesis of pubertal gynecomastia.</p><p>Pubertal gynecomastia usually resolves spontaneously within six months to two years of onset but, in some instances, may persist after completion of puberty into adulthood, resulting in persistent pubertal gynecomastia.</p><p class=\"headingAnchor\" id=\"H6318937\"><span class=\"h2\">Drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are many drugs that have been associated with gynecomastia (<a href=\"image.htm?imageKey=ENDO%2F71421\" class=\"graphic graphic_table graphicRef71421 \">table 3</a>). Drugs with the best evidence for an association with gynecomastia include <a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a>, <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">cimetidine</a>, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-drug-information\" class=\"drug drug_general\">recombinant human growth hormone</a>, estrogens, human chorionic gonadotropin (hCG), antiandrogens, gonadotropin-releasing hormone (GnRH) agonists, and 5-alpha-reductase inhibitors [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/38\" class=\"abstract_t\">38</a>]. The pathophysiologic mechanism for some, such as estrogens or antiandrogens, is quite clear. However, for others such as spironolactone, the mechanisms are multifactorial.</p><p><a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">Spironolactone</a> can increase the aromatization of testosterone to E2, decrease the testosterone production rate by the testes, and displace testosterone from sex hormone-binding globulin (SHBG), thereby increasing its metabolic clearance rate. Spironolactone also acts as an antiandrogen by binding to androgen receptors and displacing or preventing binding of testosterone and dihydrotestosterone to their receptors [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/26,39\" class=\"abstract_t\">26,39</a>].</p><p>In a placebo-controlled trial of low-dose <a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a> (25 to 50 <span class=\"nowrap\">mg/day)</span> for heart failure, endocrine side effects (gynecomastia, breast pain, impotence, and decreased libido) were seen in 10 percent compared with 3 percent in the placebo group [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/40\" class=\"abstract_t\">40</a>]. Gynecomastia will occur in almost every male who takes a large dose of spironolactone (&ge;100 <span class=\"nowrap\">mg/day),</span> eg, to treat men with liver failure or hypertension due to aldosterone excess [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/41\" class=\"abstract_t\">41</a>].</p><p>In contrast, in a study of <a href=\"topic.htm?path=eplerenone-drug-information\" class=\"drug drug_general\">eplerenone</a> (another selective mineralocorticoid receptor antagonist) in over 6500 patients with heart failure, gynecomastia, impotence, or breast pain occurred with equal frequency in the eplerenone and placebo groups (1.0 versus 1.1 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/42\" class=\"abstract_t\">42</a>]. (See <a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction&quot;</a>.)</p><p>For many of the drugs listed in the table, a clear-cut relationship between the drug ingestion and gynecomastia has not been established (<a href=\"image.htm?imageKey=ENDO%2F71421\" class=\"graphic graphic_table graphicRef71421 \">table 3</a>). For most drugs, the presumed relationship has been based upon epidemiologic studies or challenge-rechallenge studies in small numbers of individual patients [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/38,39\" class=\"abstract_t\">38,39</a>].</p><p>Drugs within the same class do not all cause gynecomastia to the same extent. Among the calcium channel blockers, <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">nifedipine</a> has the highest frequency of gynecomastia and <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a> the lowest [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/39,43\" class=\"abstract_t\">39,43</a>]. Thus, in an older man who is at increased risk of gynecomastia simply on the basis of age, diltiazem would be preferable to nifedipine.</p><p>Another example is the use of H2-receptor or proton-pump blockers; the incidence of gynecomastia is highest with <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">cimetidine</a> followed by <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">ranitidine</a> and lowest with <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a> [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/44\" class=\"abstract_t\">44</a>]. Thus, omeprazole would be a better choice in an older individual with other risk factors for developing gynecomastia.</p><p class=\"headingAnchor\" id=\"H6318949\"><span class=\"h3\">Treatment of HIV infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The breast enlargement that is seen in men with human immunodeficiency virus (HIV) receiving highly active antiretroviral therapy (HAART) is usually due to fat tissue (lipomastia or pseudogynecomastia) as part of a fat redistribution syndrome (lipodystrophy) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/45\" class=\"abstract_t\">45</a>]. However, cases of true gynecomastia have also been described, thought to be due to coexisting hypogonadism or possible estrogen-like effects of some drugs, in particular, <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-hiv-associated-lipodystrophy\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy&quot;</a> and <a href=\"topic.htm?path=treatment-of-hiv-associated-lipodystrophy\" class=\"medical medical_review\">&quot;Treatment of HIV-associated lipodystrophy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1498359345\"><span class=\"h3\">Hormone therapy for prostate cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia is common in men with prostate cancer undergoing androgen deprivation therapy, in particular with <a href=\"topic.htm?path=bicalutamide-drug-information\" class=\"drug drug_general\">bicalutamide</a>. The prevalence is as high as 75 percent when antiandrogen monotherapy is used but is only approximately 15 percent in men treated with total androgen blockade (combined GnRH agonist with an antiandrogen). This difference might be due to higher doses of antiandrogen plus persistent normal to elevated endogenous production of estrogen with antiandrogen therapy. When antiandrogens are used as monotherapy, much higher doses are used, eg, bicalutamide 150 <span class=\"nowrap\">mg/day</span> versus 50 <span class=\"nowrap\">mg/day</span> if combined with a GnRH agonist. (See <a href=\"topic.htm?path=side-effects-of-androgen-deprivation-therapy#H28\" class=\"medical medical_review\">&quot;Side effects of androgen deprivation therapy&quot;, section on 'Gynecomastia'</a>.)</p><p class=\"headingAnchor\" id=\"H1068114488\"><span class=\"h3\">Herbal products</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tea tree oil and lavender oil, plant-derived oils that are available as over-the-counter skin care products (lotions, soaps, and shampoos), have been associated with gynecomastia. This was illustrated in a report of three prepubertal boys in whom gynecomastia developed after repeated use of skin products containing the oils [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/47\" class=\"abstract_t\">47</a>]. Both oils had weak estrogenic and antiandrogenic properties in in vitro studies, and the gynecomastia resolved when the skin products were discontinued. Other environmental substances with estrogenic or antiandrogenic properties have also been reported to cause gynecomastia [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/48-50\" class=\"abstract_t\">48-50</a>]. Soy protein formulas, which contain high concentrations of phytoestrogens, were not associated with gynecomastia in one study in children [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H6318955\"><span class=\"h2\">Idiopathic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia in adults is often multifactorial. Aging per se is associated with an increase in body fat relative to the lean body mass. Adipose tissue is an active site of extraglandular aromatization of testosterone to E2 and of androstenedione to E1. In addition, there tends to be a gradual decrease in testosterone production by the aging testes and an increase in SHBG levels, resulting in a fall in the free testosterone concentration with a reciprocal increase in the luteinizing hormone (LH) level that results in increased aromatization of testosterone to estradiol [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/24,52\" class=\"abstract_t\">24,52</a>]. These two factors probably account for most patients who have &quot;idiopathic&quot; gynecomastia. Older men are also more likely to take medications associated with gynecomastia than are younger men.</p><p class=\"headingAnchor\" id=\"H6318961\"><span class=\"h2\">Cirrhosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of gynecomastia in cirrhotic patients is as high as 67 percent; however, this may not be significantly different from noncirrhotic, age-matched control patients [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/23,53\" class=\"abstract_t\">23,53</a>]. Cirrhosis is accompanied by several changes that probably explain the development of gynecomastia, including an increased production rate of androstenedione from the adrenals, enhanced aromatization of androstenedione to E1, and increased conversion of E1 to E2 [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/54\" class=\"abstract_t\">54</a>]. Additionally, many patients receive high doses of <a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a>, which can contribute to the pathogenesis of gynecomastia in this population. (See <a href=\"topic.htm?path=cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis#H71303477\" class=\"medical medical_review\">&quot;Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis&quot;, section on 'Chest findings'</a>.)</p><p class=\"headingAnchor\" id=\"H814974332\"><span class=\"h2\">Starvation and refeeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several studies were carried out on American prisoners of war who were freed at the end of World War II. Approximately 10 percent had developed gynecomastia during starvation, while between 5 and 50 percent noted breast tenderness, pain, and enlargement within two to three months of refeeding after release [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/55\" class=\"abstract_t\">55</a>]. Prior to refeeding, approximately 80 percent reported erectile dysfunction, 85 percent had decreased libido, and 73 percent showed testicular atrophy [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/56\" class=\"abstract_t\">56</a>]. (See <a href=\"topic.htm?path=causes-of-secondary-hypogonadism-in-males\" class=\"medical medical_review\">&quot;Causes of secondary hypogonadism in males&quot;</a>.)</p><p>During starvation, both gonadotropin and testosterone levels were probably reduced, while estrogen production was probably normal due to normal estrogen production from adrenal precursors. These changes will promote the development of gynecomastia. During refeeding, gonadotropins rise, resulting in both an increase in testosterone secretion and a marked elevation in E2 product (due to LH-induced increases in aromatization of testosterone) that mimics normal puberty [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/56\" class=\"abstract_t\">56</a>]. Thus, patients who develop refeeding gynecomastia may be said to have undergone a &quot;second puberty.&quot; (See <a href=\"topic.htm?path=normal-puberty#H10\" class=\"medical medical_review\">&quot;Normal puberty&quot;, section on 'Boys'</a>.)</p><p class=\"headingAnchor\" id=\"H6318967\"><span class=\"h2\">Male hypogonadism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary hypogonadism can be due to a congenital abnormality, such as Klinefelter syndrome or an enzymatic defect in the testosterone biosynthetic pathway, or to testicular trauma, infection, infiltrative disorders, vascular insufficiency, or aging (see <a href=\"topic.htm?path=causes-of-primary-hypogonadism-in-males\" class=\"medical medical_review\">&quot;Causes of primary hypogonadism in males&quot;</a>). The associated reduction in testosterone production leads to a decrease in the serum testosterone concentration and a compensatory rise in LH release. The excess LH results in enhanced Leydig cell stimulation with inhibition of the 17,20-lyase and 17-hydroxylase activities and increased aromatization of testosterone to E2; the net effect is an increase in E2 relative to testosterone secretion [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/57\" class=\"abstract_t\">57</a>].</p><p>Secondary hypogonadism due to a hypothalamic or pituitary abnormality may also be associated with gynecomastia. In these patients, the production of LH is deficient, resulting in a low testosterone production rate and low E2 production from the testes. However, the adrenal cortex continues to produce estrogen precursors that are aromatized in extraglandular tissue; the result is an increased estrogen-to-androgen ratio.</p><p>Men with hyperprolactinemia may develop gynecomastia due to prolactin's effect on reducing the secretion of gonadotropins, leading to secondary hypogonadism. Prolactin itself will stimulate milk production in breast tissue that has been primed by estrogen and progesterone but does not directly cause gynecomastia.</p><p class=\"headingAnchor\" id=\"H6318973\"><span class=\"h2\">Testicular neoplasms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Germ cell tumors account for approximately 95 percent of testicular neoplasms; between 2.5 and 6 percent of affected patients have gynecomastia at the time of presentation [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/57\" class=\"abstract_t\">57</a>]. The gynecomastia is associated with secretion of hCG by foci of choriocarcinoma or trophoblastic cells in germ cell tumors (<a href=\"image.htm?imageKey=ENDO%2F71421\" class=\"graphic graphic_table graphicRef71421 \">table 3</a>). (See <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;</a>.)</p><p>The high levels of hCG lead to Leydig cell dysfunction through inhibition of the cytochrome P450c17 enzyme, which mediates the 17,20-lyase and 17-hydroxylase activities in the testes [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/58\" class=\"abstract_t\">58</a>]. hCG also stimulates interstitial (Leydig) cell aromatase activity, which converts androgen precursors to E1 and E2. The net effect is a relative increase in E2 to testosterone production.</p><p>Gynecomastia is a poor prognostic sign if present at the time of diagnosis of the tumor. It also occurs in approximately 15 percent of patients after successful treatment with surgery, chemotherapy, or radiation therapy; at this time, it does not affect predicted survival [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/59,60\" class=\"abstract_t\">59,60</a>]. This form of gynecomastia results from hypogonadism secondary to the chemotherapy or radiation; hCG is not found in the serum. It often spontaneously resolves within one year [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/60\" class=\"abstract_t\">60</a>]. (See <a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-testicular-germ-cell-tumors\" class=\"medical medical_review\">&quot;Epidemiology of and risk factors for testicular germ cell tumors&quot;</a>.)</p><p>Gynecomastia is also found in 20 to 30 percent of patients with the less common (2 percent of all testicular tumors) Leydig cell tumors of the testes [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/61\" class=\"abstract_t\">61</a>]. These tumors are found in 6- to 10-year-old boys who present with precocious puberty and in 26- to 35-year-old men who present with a testicular mass, gynecomastia, erectile dysfunction, and loss of libido. Approximately 10 percent of these tumors are malignant. The Leydig cell tumors secrete increased quantities of E2 and also aromatize more androgen precursors to estrogens [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/62,63\" class=\"abstract_t\">62,63</a>]. In adults, testosterone production is decreased because the increased E2 levels inhibit gonadotropin secretion, which in turn leads to secondary hypogonadism. (See <a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors\" class=\"medical medical_review\">&quot;Anatomy and pathology of testicular tumors&quot;</a>.)</p><p>Large cell-calcifying Sertoli cell (sex-cord) tumors of the testes are associated with gynecomastia and feminization through excessive aromatase activity, converting androstenedione to E1 and testosterone to E2. These tumors may occur sporadically or as manifestations of two autosomal dominant disorders: Peutz-Jeghers syndrome and the Carney complex. (See <a href=\"topic.htm?path=testicular-sex-cord-stromal-tumors#H4\" class=\"medical medical_review\">&quot;Testicular sex cord stromal tumors&quot;, section on 'Sertoli cell tumors'</a>.)</p><p class=\"headingAnchor\" id=\"H6318979\"><span class=\"h2\">Hyperthyroidism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia has been reported in as many as 25 to 40 percent of men with hyperthyroidism due to Graves' disease, although one study suggests that the prevalence is less than 10 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/64-67\" class=\"abstract_t\">64-67</a>]. Serum LH levels are often elevated, contributing to increased E2 relative to testosterone production by Leydig cells [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/68,69\" class=\"abstract_t\">68,69</a>]. There is also enhanced aromatization of testosterone to E2 and of androstenedione to E1 in extraglandular tissues [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/70\" class=\"abstract_t\">70</a>]. This results in increased concentration of SHBG. Free testosterone levels are normal or low, while free E2 levels are elevated. Thus, gynecomastia results from the combination of decreased free androgen levels combined with the overproduction of estrogens. (See <a href=\"topic.htm?path=overview-of-the-clinical-manifestations-of-hyperthyroidism-in-adults#H12\" class=\"medical medical_review\">&quot;Overview of the clinical manifestations of hyperthyroidism in adults&quot;, section on 'Genitourinary'</a>.)</p><p class=\"headingAnchor\" id=\"H6318985\"><span class=\"h2\">Chronic kidney disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gynecomastia occurs in approximately 50 percent of patients treated with maintenance hemodialysis [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/71\" class=\"abstract_t\">71</a>]. The primary cause of the gynecomastia appears to be Leydig cell dysfunction. Serum testosterone levels are low, and gonadotropins are appropriately elevated; the metabolic clearance of LH is also reduced [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/72\" class=\"abstract_t\">72</a>]. Gynecomastia may occur following renal transplantation as gonadal function improves (&quot;refeeding gynecomastia&quot;) <span class=\"nowrap\">and/or</span> the use of transplantation medications such as <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>. (See <a href=\"topic.htm?path=sexual-dysfunction-in-uremic-men#H9\" class=\"medical medical_review\">&quot;Sexual dysfunction in uremic men&quot;, section on 'Gynecomastia'</a>.)</p><p class=\"headingAnchor\" id=\"H6318991\"><span class=\"h2\">Other rare causes</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Feminizing adrenal tumors </strong>&ndash;<strong> </strong>These are rare tumors that are malignant in approximately 75 percent of cases, with a median survival of 1.5 years. In a series of 52 patients, 98 percent had gynecomastia, 58 percent had a palpable tumor, and approximately 50 percent had testicular atrophy [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/73\" class=\"abstract_t\">73</a>]. Serum levels of dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, and E2 are increased, while total and free testosterone levels are reduced. Urinary 17-ketosteroid excretion is generally markedly elevated. Gonadotropin levels are usually normal or low. The combination of increased secretion of estrogens by the tumor and increased peripheral aromatization of adrenal androgens to estrogens accounts for the gynecomastia. (See <a href=\"topic.htm?path=clinical-presentation-and-evaluation-of-adrenocortical-tumors#H10\" class=\"medical medical_review\">&quot;Clinical presentation and evaluation of adrenocortical tumors&quot;, section on 'Androgen and estrogen-secreting tumors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Ectopic hCG </strong>&ndash;<strong> </strong>Increased serum levels of immunoreactive hCG are found in approximately 18 percent of patients with a wide variety of nontrophoblastic neoplasms [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/74\" class=\"abstract_t\">74</a>]. The levels of hCG are generally only modestly raised, and most patients do not exhibit clinical evidence of excess hCG production, in part because the majority of patients have production of the biologically inactive free beta subunit of hCG rather than the biologically active intact molecule. There are, however, a few exceptions:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Precocious puberty can occur in boys with hCG-secreting hepatoblastomas [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/74\" class=\"abstract_t\">74</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In adults, large cell carcinoma of the lung, gastric carcinoma, renal cell carcinoma, and, occasionally, hepatoma have been associated with gynecomastia and marked elevations of serum hCG</p><p/><p class=\"bulletIndent1\">The pathogenesis of the gynecomastia is similar to that found with hCG-secreting germ cell neoplasms of the testes. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-staging-of-testicular-germ-cell-tumors#H10\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and staging of testicular germ cell tumors&quot;, section on 'Serum tumor markers'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Disorders of sex development </strong>&ndash; Individuals with a disorder of sex development born with both testicular and ovarian tissue may develop gynecomastia from excessive estrogen secretion by the ovarian component [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/75\" class=\"abstract_t\">75</a>]. In addition, the increased estrogen production can suppress intratesticular P450c17 activity, as well as LH secretion, thereby reducing testosterone production.</p><p/><p class=\"bulletIndent1\">The androgen insensitivity syndromes are a group of disorders due to defects in or absence of the intracellular androgen receptor in androgen target tissues [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/76\" class=\"abstract_t\">76</a>]. The clinical manifestations are variable, but breast development is seen. This disorder is reviewed in detail separately. (See <a href=\"topic.htm?path=pathogenesis-and-clinical-manifestations-of-disorders-of-androgen-action\" class=\"medical medical_review\">&quot;Pathogenesis and clinical manifestations of disorders of androgen action&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Familial prepubertal gynecomastia </strong>&ndash;<strong> </strong>Familial prepubertal gynecomastia is a rare disorder of increased aromatase activity resulting in severe estrogen excess. The disorder appears to be due to heterozygous inversions or polymorphisms of the p450 aromatase gene (<em>CYP19</em>) [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/77-82\" class=\"abstract_t\">77-82</a>]. The mode of inheritance appears to be autosomal dominant [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/79,81\" class=\"abstract_t\">79,81</a>].</p><p/><p class=\"bulletIndent1\">The initial description was of an eight-year-old boy who had accelerated growth and bone maturation and severe feminization with gynecomastia due to a 50-fold increase in extraglandular conversion of plasma androstenedione to E1 [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/77\" class=\"abstract_t\">77</a>]. This child's heterosexual precocity was felt to be due to a failure of fetal aromatase activities to regress following birth.</p><p/><p class=\"bulletIndent1\">It is possible that some patients with the diagnosis of &quot;idiopathic&quot; gynecomastia actually represent excessive extraglandular aromatase activity [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\">Aromatase inhibitors, which have had limited success in the treatment of other causes of gynecomastia, may be effective in this disorder [<a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/81\" class=\"abstract_t\">81</a>].</p><p/><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=when-men-develop-breasts-gynecomastia-the-basics\" class=\"medical medical_basics\">&quot;Patient education: When men develop breasts (gynecomastia) (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=gynecomastia-breast-enlargement-in-men-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Gynecomastia (breast enlargement in men) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s) (<a href=\"image.htm?imageKey=ENDO%2F72334\" class=\"graphic graphic_figure graphicRef72334 \">figure 1</a>). Fat deposition without glandular proliferation is termed pseudogynecomastia (often seen in obese men). (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gynecomastia is common in infancy and adolescence. It is estimated that between 60 to 90 percent of infants have transient gynecomastia due to the high estrogenic milieu of pregnancy. The second peak of occurrence is during puberty, affecting approximately one- to two-thirds of boys. Spontaneous regression of breast tissue occurs in most cases. (See <a href=\"topic.htm?path=gynecomastia-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Gynecomastia in children and adolescents&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The basic mechanisms of gynecomastia include a decrease in androgen production, an increase in estrogen production, or increased availability of estrogen precursors for peripheral conversion to estrogen. Androgen receptor blockade resulting in unopposed estrogen action is another mechanism. (See <a href=\"#H4\" class=\"local\">'Pathophysiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The various conditions associated with gynecomastia are usually felt to represent an imbalance between the stimulatory effect of estrogen and the inhibitory effect of androgens. (See <a href=\"#H4\" class=\"local\">'Pathophysiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In adult patients seeking help for gynecomastia, current estimates suggest the following etiologies (<a href=\"image.htm?imageKey=ENDO%2F53468\" class=\"graphic graphic_table graphicRef53468 \">table 2</a>) (see <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H6318343\" class=\"local\">'Causes of gynecomastia'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persistent pubertal gynecomastia &ndash; 25 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Drugs &ndash; 10 to 25 percent (<a href=\"image.htm?imageKey=ENDO%2F71421\" class=\"graphic graphic_table graphicRef71421 \">table 3</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>No detectable abnormality &ndash; 25 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cirrhosis or malnutrition &ndash; 8 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Male hypogonadism &ndash; Primary (8 percent), secondary (2 percent)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Testicular tumors &ndash; 3 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hyperthyroidism &ndash; 1.5 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Chronic kidney disease &ndash; 1 percent</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Braunstein GD. Pubertal gynecomastia. In: Pediatric Endocrinology, Lifshitz F (Ed), Marcel Dekker, New York 1996. p.197.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/2\" class=\"nounderline abstract_t\">Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</a></li><li class=\"breakAll\">Moore MP. Male breast cancer. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (Eds), Lippincott-Raven, Philadelphia 1996. p.859.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/4\" class=\"nounderline abstract_t\">Schmidt-Voigt J. Brustdruenschwellungen bei mannlichen Jugendlichen des Pubertatsalters (Pubertatsmakromastie). Z Kinderheilkd 1941; 62:590.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/5\" class=\"nounderline abstract_t\">Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/6\" class=\"nounderline abstract_t\">NYDICK M, BUSTOS J, DALE JH Jr, RAWSON RW. Gynecomastia in adolescent boys. JAMA 1961; 178:449.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/7\" class=\"nounderline abstract_t\">Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975; 86:212.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/8\" class=\"nounderline abstract_t\">Fara GM, Del Corvo G, Bernuzzi S, et al. Epidemic of breast enlargement in an Italian school. Lancet 1979; 2:295.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/9\" class=\"nounderline abstract_t\">Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr 1979; 95:293.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/10\" class=\"nounderline abstract_t\">Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984; 58:492.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/11\" class=\"nounderline abstract_t\">Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990; 116:450.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/12\" class=\"nounderline abstract_t\">Kumanov P, Deepinder F, Robeva R, et al. Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 2007; 41:126.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/13\" class=\"nounderline abstract_t\">WILLIAMS MJ. Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963; 34:103.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/14\" class=\"nounderline abstract_t\">Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979; 48:338.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/15\" class=\"nounderline abstract_t\">Carlson HE. Gynecomastia. N Engl J Med 1980; 303:795.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/16\" class=\"nounderline abstract_t\">Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med 1984; 77:633.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/17\" class=\"nounderline abstract_t\">Murray NP, Daly MJ. Gynaecomastia and heart failure--adverse drug reaction or disease process? J Clin Pharm Ther 1991; 16:275.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/18\" class=\"nounderline abstract_t\">Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 1994; 21:579.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/19\" class=\"nounderline abstract_t\">O'Hanlon DM, Kent P, Kerin MJ, Given HF. Unilateral breast masses in men over 40: a diagnostic dilemma. Am J Surg 1995; 170:24.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/20\" class=\"nounderline abstract_t\">Volpe CM, Raffetto JD, Collure DW, et al. Unilateral male breast masses: cancer risk and their evaluation and management. Am Surg 1999; 65:250.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/21\" class=\"nounderline abstract_t\">Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med 1980; 25:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/22\" class=\"nounderline abstract_t\">Rochefort H, Garcia M. The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 1983; 23:193.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/23\" class=\"nounderline abstract_t\">Edmondson HA, Glass SJ, Soll SN. Gynecomastia associated with cirrhosis of the liver. Proc Soc Exp Biol Med 1939; 42:97.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/24\" class=\"nounderline abstract_t\">Smals AG. Gynaecomastia. Neth J Med 1987; 31:47.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/25\" class=\"nounderline abstract_t\">Weinstein RL, Kelch RP, Jenner MR, et al. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest 1974; 53:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/26\" class=\"nounderline abstract_t\">Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977; 87:398.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/27\" class=\"nounderline abstract_t\">Grosso DS, Boyden TW, Pamenter RW, et al. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother 1983; 23:207.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/28\" class=\"nounderline abstract_t\">Bulard J, Mowszowicz I, Schaison G. Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia. J Clin Endocrinol Metab 1987; 64:618.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/29\" class=\"nounderline abstract_t\">Ers&ouml;z H&ouml;, Onde ME, Terekeci H, et al. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia. Int J Androl 2002; 25:312.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/30\" class=\"nounderline abstract_t\">Knorr D, Bidlingmaier F. Gynaecomastia in male adolescents. Clin Endocrinol Metab 1975; 4:157.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/31\" class=\"nounderline abstract_t\">Bidlingmaier F, Knorr D. Plasma testosterone and estrogens in pubertal gynecomastia. Z Kinderheilkd 1973; 115:89.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/32\" class=\"nounderline abstract_t\">Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynaecomastia. Clin Endocrinol (Oxf) 1979; 11:505.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/33\" class=\"nounderline abstract_t\">LaFranchi SH, Parlow AF, Lippe BM, et al. Pubertal gynecomastia and transient elevation of serum estradiol level. Am J Dis Child 1975; 129:927.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/34\" class=\"nounderline abstract_t\">Limony Y, Friger M, Hochberg Z. Pubertal gynecomastia coincides with peak height velocity. J Clin Res Pediatr Endocrinol 2013; 5:142.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/35\" class=\"nounderline abstract_t\">Mieritz MG, Sorensen K, Aksglaede L, et al. Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia. Clin Endocrinol (Oxf) 2014; 80:691.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/36\" class=\"nounderline abstract_t\">Mieritz MG, Rak&ecirc;t LL, Hagen CP, et al. A Longitudinal Study of Growth, Sex Steroids, and IGF-1 in Boys With Physiological Gynecomastia. J Clin Endocrinol Metab 2015; 100:3752.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/37\" class=\"nounderline abstract_t\">Dundar B, Dundar N, Erci T, et al. Leptin levels in boys with pubertal gynecomastia. J Pediatr Endocrinol Metab 2005; 18:929.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/38\" class=\"nounderline abstract_t\">Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf 2012; 11:779.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/39\" class=\"nounderline abstract_t\">Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993; 13:37.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/40\" class=\"nounderline abstract_t\">Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/41\" class=\"nounderline abstract_t\">Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131:105.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/42\" class=\"nounderline abstract_t\">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/43\" class=\"nounderline abstract_t\">Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988; 148:379.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/44\" class=\"nounderline abstract_t\">Garc&iacute;a Rodr&iacute;guez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994; 308:503.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/45\" class=\"nounderline abstract_t\">Gewurz BE, Dezube BJ, Pantanowitz L. HIV and the breast. AIDS Read 2005; 15:392.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/46\" class=\"nounderline abstract_t\">Jover F, Cuadrado JM, Roig P, et al. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J 2004; 10:244.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/47\" class=\"nounderline abstract_t\">Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356:479.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/48\" class=\"nounderline abstract_t\">Finkelstein JS, McCully WF, MacLaughlin DT, et al. The mortician's mystery. Gynecomastia and reversible hypogonadotropic hypogonadism in an embalmer. N Engl J Med 1988; 318:961.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/49\" class=\"nounderline abstract_t\">Brody SA, Loriaux DL. Epidemic of gynecomastia among haitian refugees: exposure to an environmental antiandrogen. Endocr Pract 2003; 9:370.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/50\" class=\"nounderline abstract_t\">Braunstein GD. Environmental gynecomastia. Endocr Pract 2008; 14:409.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/51\" class=\"nounderline abstract_t\">Giampietro PG, Bruno G, Furcolo G, et al. Soy protein formulas in children: no hormonal effects in long-term feeding. J Pediatr Endocrinol Metab 2004; 17:191.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/52\" class=\"nounderline abstract_t\">Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med 1993; 159:579.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/53\" class=\"nounderline abstract_t\">Cavanaugh J, Niewoehner CB, Nuttall FQ. Gynecomastia and cirrhosis of the liver. Arch Intern Med 1990; 150:563.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/54\" class=\"nounderline abstract_t\">Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab 1975; 40:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/55\" class=\"nounderline abstract_t\">JACOBS EC. Gynecomastia following severe starvation. Ann Intern Med 1948; 28:792.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/56\" class=\"nounderline abstract_t\">Smith SR, Chhetri MK, Johanson J, et al. The pituitary-gonadal axis in men with protein-calorie malnutrition. J Clin Endocrinol Metab 1975; 41:60.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/57\" class=\"nounderline abstract_t\">Tseng A Jr, Horning SJ, Freiha FS, et al. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer 1985; 56:2534.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/58\" class=\"nounderline abstract_t\">Forest MG, Lecoq A, Saez JM. Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J Clin Endocrinol Metab 1979; 49:284.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/59\" class=\"nounderline abstract_t\">Turner AR, Morrish DW, Berry J, MacDonald RN. Gynecomastia after cytotoxic therapy for metastatic testicular cancer. Arch Intern Med 1982; 142:896.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/60\" class=\"nounderline abstract_t\">Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/61\" class=\"nounderline abstract_t\">Bercovici JP, Tater D, Khoury S, et al. Leydig cell tumor with gynecomastia: hormonal effects of an estrogen-producing tumor. J Clin Endocrinol Metab 1981; 53:1291.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/62\" class=\"nounderline abstract_t\">Bercovici JP, Nahoul K, Ducasse M, et al. Leydig cell tumor with gynecomastia: further studies--the recovery after unilateral orchidectomy. J Clin Endocrinol Metab 1985; 61:957.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/63\" class=\"nounderline abstract_t\">Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999; 6:315.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/64\" class=\"nounderline abstract_t\">Chopra IJ, Tulchinsky D. Status of estrogen-androgen balance in hyperthyroid men with Graves' disease. J Clin Endocrinol Metab 1974; 38:269.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/65\" class=\"nounderline abstract_t\">Ashkar FS, Smoak WM 3rd, Gilson AJ, Miller R. Gynecomastia and mastoplasia in Graves' disease. Metabolism 1970; 19:946.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/66\" class=\"nounderline abstract_t\">Chan WB, Yeung VT, Chow CC, et al. Gynaecomastia as a presenting feature of thyrotoxicosis. Postgrad Med J 1999; 75:229.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/67\" class=\"nounderline abstract_t\">Bercovici JP, Mauvais-Jarvis P. Hyperthyroidism and gynecomastia: metabolic studies. J Clin Endocrinol Metab 1972; 35:671.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/68\" class=\"nounderline abstract_t\">Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3:69.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/69\" class=\"nounderline abstract_t\">Abalovich M, Levalle O, Hermes R, et al. Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males. Thyroid 1999; 9:857.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/70\" class=\"nounderline abstract_t\">Olivo J, Gordon GG, Rafii F, Southren AL. Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver. Steroids 1975; 26:47.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/71\" class=\"nounderline abstract_t\">Freeman RM, Lawton RL, Fearing MO. Gynecomastia: an endocrinologic complication of hemodialysis. Ann Intern Med 1968; 69:67.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/72\" class=\"nounderline abstract_t\">Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977; 296:1245.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/73\" class=\"nounderline abstract_t\">GABRILOVE JL, SHARMA DC, WOTIZ HH, DORFMAN RI. FEMINIZING ADRENOCORTICAL TUMORS IN THE MALE. A REVIEW OF 52 CASES INCLUDING A CASE REPORT. Medicine (Baltimore) 1965; 44:37.</a></li><li class=\"breakAll\">Braunstein GD. Placental proteins as tumor markers. In: Immunodiagnosis of cancer, Herberman RB, Mercer DW (Eds), Marcel Dekker, New York 1990. p.673.</li><li class=\"breakAll\">van Niekerk WA. True hermaphroditism. In: The Intersex Child, Josso N (Ed), S Karger AG, Basel, Switzerland 1981. p.80.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/76\" class=\"nounderline abstract_t\">Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16:271.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/77\" class=\"nounderline abstract_t\">Hemsell DL, Edman CD, Marks JF, et al. Massive extranglandular aromatization of plasma androstenedione resulting in feminization of a prepubertal boy. J Clin Invest 1977; 60:455.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/78\" class=\"nounderline abstract_t\">Berkovitz GD, Guerami A, Brown TR, et al. Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids. J Clin Invest 1985; 75:1763.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/79\" class=\"nounderline abstract_t\">Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998; 83:1348.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/80\" class=\"nounderline abstract_t\">Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/81\" class=\"nounderline abstract_t\">Binder G, Iliev DI, Dufke A, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005; 90:484.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-pathophysiology-and-causes-of-gynecomastia/abstract/82\" class=\"nounderline abstract_t\">Fukami M, Tsuchiya T, Vollbach H, et al. Genomic basis of aromatase excess syndrome: recombination- and replication-mediated rearrangements leading to CYP19A1 overexpression. J Clin Endocrinol Metab 2013; 98:E2013.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7466 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DEFINITIONS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">PATHOPHYSIOLOGY</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">In utero</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Estrogen in men</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Sex hormone-binding globulin</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Imbalance between estrogen and androgen</a></li><li><a href=\"#H612304741\" id=\"outline-link-H612304741\">Obesity</a></li></ul></li><li><a href=\"#H6318343\" id=\"outline-link-H6318343\">CAUSES OF GYNECOMASTIA</a><ul><li><a href=\"#H1068114220\" id=\"outline-link-H1068114220\">Physiologic</a><ul><li><a href=\"#H1292581444\" id=\"outline-link-H1292581444\">- Puberty</a></li></ul></li><li><a href=\"#H6318937\" id=\"outline-link-H6318937\">Drugs</a><ul><li><a href=\"#H6318949\" id=\"outline-link-H6318949\">- Treatment of HIV infection</a></li><li><a href=\"#H1498359345\" id=\"outline-link-H1498359345\">- Hormone therapy for prostate cancer</a></li><li><a href=\"#H1068114488\" id=\"outline-link-H1068114488\">- Herbal products</a></li></ul></li><li><a href=\"#H6318955\" id=\"outline-link-H6318955\">Idiopathic</a></li><li><a href=\"#H6318961\" id=\"outline-link-H6318961\">Cirrhosis</a></li><li><a href=\"#H814974332\" id=\"outline-link-H814974332\">Starvation and refeeding</a></li><li><a href=\"#H6318967\" id=\"outline-link-H6318967\">Male hypogonadism</a></li><li><a href=\"#H6318973\" id=\"outline-link-H6318973\">Testicular neoplasms</a></li><li><a href=\"#H6318979\" id=\"outline-link-H6318979\">Hyperthyroidism</a></li><li><a href=\"#H6318985\" id=\"outline-link-H6318985\">Chronic kidney disease</a></li><li><a href=\"#H6318991\" id=\"outline-link-H6318991\">Other rare causes</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H10403929\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/7466|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/72334\" class=\"graphic graphic_figure\">- Exam for gynecomastia</a></li><li><a href=\"image.htm?imageKey=ENDO/64368\" class=\"graphic graphic_figure\">- Prevalence of gynecomastia</a></li><li><a href=\"image.htm?imageKey=ENDO/58706\" class=\"graphic graphic_figure\">- Sex hormone production males</a></li></ul></li><li><div id=\"ENDO/7466|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/76165\" class=\"graphic graphic_table\">- Tanner stages of male puberty</a></li><li><a href=\"image.htm?imageKey=ENDO/53468\" class=\"graphic graphic_table\">- Causes of gynecomastia</a></li><li><a href=\"image.htm?imageKey=ENDO/71421\" class=\"graphic graphic_table\">- Drugs and gynecomastia</a></li><li><a href=\"image.htm?imageKey=ENDO/53166\" class=\"graphic graphic_table\">- Pathophysiology gynecomastia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anatomy-and-pathology-of-testicular-tumors\" class=\"medical medical_review\">Anatomy and pathology of testicular tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-primary-hypogonadism-in-males\" class=\"medical medical_review\">Causes of primary hypogonadism in males</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-secondary-hypogonadism-in-males\" class=\"medical medical_review\">Causes of secondary hypogonadism in males</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cirrhosis-in-adults-etiologies-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-evaluation-of-gynecomastia-in-adults\" class=\"medical medical_review\">Clinical features, diagnosis, and evaluation of gynecomastia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-staging-of-testicular-germ-cell-tumors\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and staging of testicular germ cell tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-evaluation-of-adrenocortical-tumors\" class=\"medical medical_review\">Clinical presentation and evaluation of adrenocortical tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-testicular-germ-cell-tumors\" class=\"medical medical_review\">Epidemiology of and risk factors for testicular germ cell tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-hiv-associated-lipodystrophy\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gynecomastia-in-children-and-adolescents\" class=\"medical medical_review\">Gynecomastia in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=male-reproductive-physiology\" class=\"medical medical_review\">Male reproductive physiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-gynecomastia\" class=\"medical medical_review\">Management of gynecomastia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=normal-puberty\" class=\"medical medical_review\">Normal puberty</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-clinical-manifestations-of-hyperthyroidism-in-adults\" class=\"medical medical_review\">Overview of the clinical manifestations of hyperthyroidism in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-and-clinical-manifestations-of-disorders-of-androgen-action\" class=\"medical medical_review\">Pathogenesis and clinical manifestations of disorders of androgen action</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gynecomastia-breast-enlargement-in-men-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Gynecomastia (breast enlargement in men) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=when-men-develop-breasts-gynecomastia-the-basics\" class=\"medical medical_basics\">Patient education: When men develop breasts (gynecomastia) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=placental-development-and-physiology\" class=\"medical medical_review\">Placental development and physiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sexual-dysfunction-in-uremic-men\" class=\"medical medical_review\">Sexual dysfunction in uremic men</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=side-effects-of-androgen-deprivation-therapy\" class=\"medical medical_review\">Side effects of androgen deprivation therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=testicular-sex-cord-stromal-tumors\" class=\"medical medical_review\">Testicular sex cord stromal tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hiv-associated-lipodystrophy\" class=\"medical medical_review\">Treatment of HIV-associated lipodystrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction</a></li></ul></div></div>","javascript":null}